Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Migraine Headaches (US)

Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262 (www.pipelinereview.com)
Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.
Analysis of: Seroquel XR Receives Approval From FDA for Maintenance Treatment of Schizophrenia (pharmalive.com)
I believe this will only enhance our arenal for the treament of schizophrenia and bipolar disorder in that the long acting version will enhance compliance and maintain better levels of the drug in patients.
Analysis of: FDA approves Lilly's Evista for breast cancer (www.marketwatch.com)
Evista sales may improve due to the FDA approval for both prevention of invasive breast cancer and osteoporosis but the increase is likely to be very modest.  It has advantages over tamoxifen in that Evista does not cause endometrial hyperplasia or cancer of the uterus, however it still carries...
September 3, 2007
gsk market analysis
Analysis of: GSK Receives Decision From FDA On Advair 500/50 For COPD (www.medicalnewstoday.com)
little effect expected.  Generally we use inhaled corticosteriod in lower doses for copd.  There tends to be less of an inflammatory component.  The salmeterol component does show significant reduction in day to day symptoms.
August 14, 2007
cost and reimbursement
Analysis of: Doctor Shortage Hurts A Coverage-for-All Plan (online.wsj.com)
This article summarizes the key problems:  Patient abundence, physician shortages and poor reimbursement for services provided.  Commonly the under insured are sicker and utilize more resources and time to get organized and managed.
Analysis of: Doctor Shortage Hurts A Coverage-for-All Plan (online.wsj.com)
The difficulty with the concept of health insurance as it now exists in this country is that it really isn't health insurance. Rather it is an amalgam of prepaid health care and catastrophic insurance. Providing coverage will not protect the system from becoming bankrupt and will not graduate more doctors...
Analysis of: AMA warns of threat to doctors' pay (pressherald.mainetoday.com)
I own a small Family Practice in Stone Harbor, NJ.  Currently my practice consists of approximately 40% Medicare patients.  If the proposed decreases in physician reimbursement occur, I may need to stop taking any new Medicare patients.  This will create more difficulty in access to care...
Analysis of: AMA Discloses Masterfile Physician Data to Pharmaceutical Companies (www.medscape.com)
The AMA leadership has again failed to assess the implication of backdoor business negotiations for its image and standing inthe medical community and general public.
Analysis of: Drugmakers convicted of overcharging (ebn.benefitnews.com)
Pharmaceutical companies have come under intense scrutiny recently regarding their corporate behavior. Though headlines will read that corporations were convicted of price manipulation, there must exist a culture borne by management who decided that the cost of a lawsuit or fine was mitigated by the...
Analysis of: DexCom Receives FDA Approval For 7-Day STS Continuous Glucose Monitoring System (www.medicaldesignonline.com)
3 day monitoring vs  7 day!  -  Competition for Medtronics Depending on cost structure and outcomes data - might be preferred by physicians/clinics and insurers to the 3 day medtronic monitoring systems. 

Previous Page : 1 2 3 Next11 to 20 of 28

Analytics


Generated at 2009-01-07T19:00:58.307